Answers are grounded in this paper and cite their sources.
Background: Patients with Acute Myeloid Leukemia (AML) experience profound neutropenia; infections remain the leading cause of morbidity and mortality.Transfusion of functional non-irradiated allogeneic granulocytes may treat or prevent infections in AML patients, and may also have anti-leukemic benefits. Study Design:Patients free of infection, with a diagnosis of AML or high-risk myelodysplastic syndrome undergoing induction or first-salvage therapy were eligible.Allogeneic Granulocyte Transfusions (GTs) were administered to neutropenic (<0.5 × 10 9 /L) patients every 3-4 days until sustained ANC recovery, initiation of new therapy, or completion of 6 weeks on study.Results: 45 patients enrolled with a median age of 67 years (range 23-83); 27 (60%) were male.Five patients (11%) never received a GT, due to donor screening failure and/or donor unavailability.119 donors donated 156 granulocyte concentrates to the remaining 40 patients.The median number of GTs transfused per patient was 3 (range 1-9).All patients experienced >1 neutropenic fever, with an average of one infectious episode per patient.Other adverse reactions were urticaria/pruritis (n=1), rash (n=1), and hypotension (n=1).Response to leukemiadirected therapy included complete remission in 50%, overall response rate of 70%, and 8-week mortality of 8%.Median overall survival was 15 months, with 51% 1-year survival.Conclusion: Administration of non-irradiated functional allogeneic GTs to neutropenic MDS/AML patients is safe and feasible.No transfusion-associated graft-versus-host-disease (TA-GVHD) was reported and no increased toxicity was described, including among the 10% receiving subsequent allogeneic stem cell transplant.The favorable patient outcomes within this diverse group of primarily elderly AML are notable.
No takes yet. Share an insight, caveat, or question.
Aung et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: